[ET Net News Agency, 21 July 2021] China Resources Pharmaceutical Group Limited (03320)
said its subsidiary Beijing Pharmaceutical Investment and Management (BVI) Limited has
agreed to buy an aggregate of 51,458,400 ordinary shares of Immunotech Biopharm Ltd
(Immunotech) (06978) (representing 10% of the total issued share capital of Immunotech) at
a total consideration of approximately HK$799.66 million, representing a price of HK$15.54
per share.
Cellular immunotherapy is an important development direction for tumour therapy in the
future. Through the proposed acquisition, it is expected that the group can complete its
strategic layout in the field of cellular immunotherapy. Immunotech together with its
subsidiaries has been deeply involved in the field of cellular immunotherapy for around 15
years, has established an experienced research and development team and full-scale
technology platform, and has obtained the relevant intellectual property rights for its
core technology and products. (RC)